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reduction in diabetes related complications and the lower frequency of SMBG 
tests. Remaining extra annual costs for SAP were 1,258 € per patient. When indirect 
costs were considered, the ICER was reduced to 23,300 € per QALY. ConClusions: 
Using a well-accepted simulation model in an uncontrolled T1DM, projection of 
the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in France. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range 
of assumptions.
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objeCtives: To investigate the costs and cost-effectiveness of a short message 
service (SMS) intervention to prevent the onset of type 2 diabetes mellitus (T2DM) 
in subjects with impaired glucose tolerance (IGT). Methods: A Markov model was 
developed to simulate the cost and effectiveness outcomes of the SMS interven-
tion and usual clinical practice from the health service provider’s perspective. The 
annual transition probabilities between health states were taken from several 
data sources, including Diabetes Prevention Program and Diabetes Prevention 
Program Outcome Study. The direct program costs and the two-year SMS interven-
tion costs were evaluated in subjects with IGT. All costs were expressed in year 
2011 U.S. dollars. The incremental cost-effectiveness ratio were calculated as cost 
per T2DM onset prevented, cost per life year gained and cost per quality adjusted 
life year (QALY) gained. Both base-case scenario and sensitivity analysis were 
conducted. Results: Within the two-year trial period, the net intervention cost 
of the SMS group was $42.03 per subject. The SMS intervention managed to reduce 
5.05% onset of diabetes, resulting in saving $118.39 per subject over two years. 
In the lifetime model, the SMS intervention dominated the control by gaining 
an additional 0.071 QALY and saving $1020.35 per person. The SMS interven-
tion remained dominance in all sensitivity analyses. ConClusions: This study 
revealed that the SMS intervention for subjects with IGT had the superiority of 
lower monetary cost and a considerable improvement in preventing or delaying 
the T2DM onset.
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objeCtives: To evaluate the cost of using the first-in-class sodium-glucose co-
transporter-2 (SGLT-2) inhibitor dapagliflozin compared to the glucagon-like pep-
tide-1 (GLP-1) analogue lixisenatide, when added to insulin for the treatment of 
patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled on 
insulin alone. Methods: Bucher indirect comparisons and a network meta-analy-
sis were performed in the add-on to insulin population with regards to the key T2DM 
outcomes of HbA1c, weight and hypoglycaemia. Dapagliflozin had similar treat-
ment effects to lixisenatide, with no statistically significant differences between 
dapagliflozin and lixisenatide in these outcomes. Therefore, a cost-minimisation 
analysis over a 1-year time horizon was developed from a UK health care perspec-
tive. Drug and administration costs, including a nurse consultation, were considered 
in the model. Drug costs were those of the British National Formulary (September 
2013), device costs were taken from the Information Services Division Drug Tariff 
2013 and the cost of a nurse consultation was estimated using the Unit Costs of 
Health and Social Care report compiled by the Personal Social Services Research 
Unit. The application of an annual discount rate of 3.5% and use of a longer time 
horizon (up to 5 years) were explored in scenario analyses. Results: Dapagliflozin 
was associated with a yearly cost of £476.96 per patient. The cost per patient for 
lixisenatide was £765.76 in the first year and £752.07 in subsequent years. Therefore, 
dapagliflozin was cost-saving compared to lixisenatide, driven by the difference 
in drug and administration costs. Applying the annual discount rate and using a 
longer time horizon, dapagliflozin was associated with savings of £1,255.30 over 5 
years compared to lixisenatide. ConClusions: Dapagliflozin in combination with 
insulin was shown to be a cost-saving treatment option compared to lixisenatide 
from a UK health care perspective for patients with T2DM who are inadequately 
controlled on insulin alone.
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objeCtives: Acromegaly is a chronic and debilitating disease, which can lead 
to significant increases in health care costs. The objective of the present study 
was to undertake an economic evaluation of Lanreotide Autogel compared with 
Octreotide LAR in the management of acromegaly in the Greek health care set-
ting. Methods: A cost minimization model was developed for the analysis which 
only considers the costs of treatment, as the two drugs have equal efficacy. The 
time horizon was 30 years; future costs were discounted at 3.5%. In addition, 
a budget impact analysis was conducted, with a time horizon of 5 years. The 
perspective for both analyses was that of Social Insurance. Data on resource use 
(administration setting, drug wastage and time required for the administration of 
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objeCtives: To synthesize and analyze the available information on the thera-
peutic value of dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 
diabetes mellitus (T2DM) from the point of view of their efficiency or cost-effective-
ness. Methods: A systematic review of national (MEDES, IBECS) and international 
(MedLine/PubMed, Cochrane Library, ISI WOK, SCOPUS) databases was performed. 
Eligible studies were economic evaluations (cost-effectiveness, cost-utility and cost-
benefit analysis) comparing costs and clinical benefits of two alternatives for the 
T2DM treatment including DPP-4 inhibitors, published in English or Spanish until 
June 2013. Studies providing data concerning costs and/or disease burden only were 
excluded. Results: Of 1,634 publications initially selected, 284 were excluded by 
duplicate review, 1,330 by title/abstract review and 8 by criteria accomplishment. A 
total of 12 publications [1 conducted in 6 countries including Spain, 4 in Europe, 4 
in USA and 3 in others] were selected. All studies were cost-effectiveness or cost-
utility analysis [discrete-event simulation (n= 8), Markov (n= 3) and others (n= 1)] 
Time horizon ranged from one year (n= 1) to lifetime (n= 7), considering 20 years 
(n= 1), 35 years (n= 2), and 40 years (n= 1). National Health System perspective was 
adopted in all publications (n= 12). One study did not include a sensitivity analysis. 
Results showed that T2DM therapy with DPP-4 inhibitors and metformin resulted 
cost-effective compared with sulfonylureas plus metformin in all countries which 
were evaluated (Sweden, UK, Germany, Portugal, Austria, Finland, Spain, USA and 
Argentina). Although DPP-4 inhibitors cost was higher compared with sulfonylureas, 
DPP-4 inhibitors plus metformin were associated to higher clinical benefits versus 
sulfonylureas plus metformin in terms of decreasing hypoglycemia incidence and 
T2DM complications. ConClusions: DPP-4 inhibitors added to metformin are a 
cost-effective alternative compared with sulfonylureas plus metformin in T2DM 
patients, mainly due to a lower hypoglycemia incidence and T2DM complications.
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) of 
type 1 diabetes (T1DM) in the UK. Methods: The Core Diabetes Model was used 
to project the incidence of diabetes-related complications over a lifetime horizon, 
based on A) a published meta-analysis comparing SAP versus CSII, and B) a real 
life observational study. The meta-analysis showed that for the analysed cohort of 
T1DM with average baseline HbA1c of 10%, every day use of SAP led to a reduction 
of -1.49% versus -0.62% HbA1c, for CGM and CSII respectively. The mean baseline 
age of the simulated cohort was 27 years, with a mean duration of diabetes of 13 
years. SAP effects also included a decrease in the annual rate of major hypoglycae-
mic events from 2.2 events per 100 patients’ month for CSII to 0. The quality of life 
was adjusted for a reduced fear of hypoglycaemic event in the SAP arm. Sensitivity 
analyses were carried out on several key parameters. Results: The incremental 
cost-effectiveness ratio (ICER) was 16,986 GBP (£) per Quality Adjusted Life Year 
gained (QALY). The improvement in discounted QALY was 3.1 years in favour of SAP. 
Additional SAP related costs were partially offset by the savings due to the reduction 
in diabetes related complications and the lower frequency of SMBG tests. Remaining 
extra costs due to SAP were on average 1,143£ per year. When a societal perspective 
was considered, ICER was reduced to 8,462 £ per QALY. ConClusions: Projection 
of the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in the UK. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range of 
assumptions.
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) 
in uncontrolled type 1 diabetes (T1DM) in France. Methods: The Core Diabetes 
Model was used to project the incidence of diabetes-related complications over 
a lifetime horizon, based on a recently performed meta-analysis comparing SAP 
versus CSII. The meta-analysis showed that for the analysed cohort of T1DM using 
exclusively Medtronic devices with average baseline HbA1c of 9%, 70% use of SAP 
led to a reduction of -0.88% versus -0.47% HbA1c, for SAP and CSII respectively. 
The mean baseline age of the simulated cohort was, according to a French typi-
cal TD1M population, 36 years, with a mean duration of diabetes of 17 years. The 
quality of life was adjusted for a reduced fear of hypoglycaemic event in the SAP 
arm. Sensitivity analyses were carried out on several key parameters. Results: 
The incremental cost-effectiveness ratio (ICER) was 27,796 € per Quality Adjusted 
Life Year gained (QALY). The improvement in discounted QALY was 1.27 years in 
favour of SAP. Undiscounted life expectancy was increased by 1 year for SAP versus 
CSII. Additional SAP related costs were partially offset by the savings due to the 
